High-resistance inspiratory muscle training to improve heart, blood vessel, and kidney health in young people with type 2 diabetes
Official title: Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes
Run by Seattle Children's Hospital · NCT06936670 · Data updated 2026-11-12
This trial will test whether about 5 minutes a day of high-resistance inspiratory muscle strength training can lower blood pressure and improve vascular and kidney function in youth and young adults with type 2 diabetes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 40 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Seattle Children's Hospital Academic / other |
| Locations | 2 sites (Seattle, Washington and 1 other locations) |
| Status | Recruiting |
| Started | April 30, 2025 |
| Main results expected | February 28, 2026 |
| Study ends | February 28, 2026 |
| Registry record updated | June 13, 2025 |
| Trial ID | NCT06936670 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 14–40 with type 2 diabetes for at least one year, HbA1c under 12%, and without advanced kidney disease or uncontrolled severe hypertension.
✕Probably not a fit
People with very long-standing diabetes, significant kidney impairment (eGFR <60 ml/min/1.73 m2 or very high albuminuria), or uncontrolled blood pressure are unlikely to be eligible and may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants aged 14–40 with at least one year of type 2 diabetes and HbA1c <12% are randomized to 3 months of daily high-resistance, short-duration inspiratory muscle strength training (30 resisted inhalations, ~5 min/day) or sham training. The study measures casual and 24-hour systolic blood pressure, endothelial function, and arterial stiffness, and evaluates kidney function through eGFR and albuminuria before and after the intervention. Translational mechanistic assays will examine nitric oxide bioavailability, endothelial nitric oxide synthase activation, and markers of oxidative stress and circulating factors to explore how IMST may work. The intervention is delivered at sites in Seattle with in-person assessments at baseline and follow-up.
Why it matters
Potential benefit: If successful, this brief daily breathing exercise could reduce blood pressure and improve vascular and kidney health with minimal time burden.
How similar studies have gone: Small adult trials of high-resistance IMST have shown reductions in systolic blood pressure and improvements in vascular function, but its effects in youth with type 2 diabetes are largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Aged 14-40, have had T2D for a least one year, HbA1C less than 12%. \- Exclusion Criteria: Have had type II diabetes for more than 18 years, estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2 or Albumin-to-creatinine ratio (ACR) greater than 2200mg/g, blood pressure greater than 160/100 mm Hg. \-
Where it's running
-
Seattle Children's Hospital
Seattle, Washington, United States Recruiting -
University of Washington Medicine Diabetes Institute
Seattle, Washington, United States Not yet recruiting
Study contacts
- Study coordinator: Kalie Tommerdahl, MD
- Email: ktomme@uw.edu
- Phone: (206) 616-9015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.